Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at IRONWOOD PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. IRONWOOD PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. IRONWOOD PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Michael Shetzline M.D., Ph.D.
Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development
Total Cash $842,900 Equity $1,734,924 Other $17,550 Total Compensation $2,595,374
Thomas McCourt
Chief Executive Officer
Total Cash $1,584,448 Equity $5,974,255 Other $24,567 Total Compensation $7,583,270
Sravan Emany
Senior Vice President, Chief Financial Officer
Total Cash $896,335 Equity $1,843,347 Other $17,550 Total Compensation $2,757,232
John Minardo
Senior Vice President, Chief Legal Officer and Secretary
Total Cash $796,856 Equity $1,626,486 Other $17,550 Total Compensation $2,440,892
Andrew Davis
Senior Vice President, Chief Business Officer
Total Cash $802,175 Equity $1,843,347 Other $22,185 Total Compensation $2,667,707
For its 2023 fiscal year, IRONWOOD PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Thomas McCourt CEO Pay $7,583,270 Median Employee Pay $275,531 CEO Pay Ratio 28:1
For its 2023 fiscal year, IRONWOOD PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alexander Denner, Ph.D. Total Cash $300,686
Andrew Dreyfus Total Cash $310,710
Catherine Moukheibir Total Cash $310,688
Jay Shepard Total Cash $300,710
Jon Duane Total Cash $305,710
Julie McHugh Total Cash $335,710
Mark Currie, Ph.D. Total Cash $300,710
Marla Kessler Total Cash $300,710

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.